AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyAnimal studyNot reportedPublished in a peer-reviewed journal
Effects of Inhibiting SPP1 on Immune Cell Migration in Mice
Researchers found a specific population of microglia in MS characterized by high levels of SPP1. This SPP1 interacts with endothelial cells, activating signals that enhance the recruitment of immune cells into the CNS. Blocking SPP1 in living mice led to reduced immune cell migration and less severe disease symptoms in an MS model.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This study highlights a potential mechanism through which MS-related inflammation occurs and suggests that targeting SPP1 might help manage immune responses in MS.
What this does not prove
Results were observed in a mouse model, which may not fully correspond to human MS. Human efficacy remains unknown.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-07-29
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceBlocking the microglia-endothelial axis via SPP1-ITGAV disruption attenuates neuroinflammation in multiple sclerosis. ↗DOI: 10.1186/s12967-026-08735-5
Supporting passages (8)
speciesMeSH terms: Animals; Osteopontin; Multiple Sclerosis; Microglia; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Mice, Inbred C57BL; Signal Transduction; Humans; Neuroinflammatory Diseases; Integrin alpha4; Inflammation; Mice; Blood-Brain Barrier
publication datePublication date: 2026-07-29
interventionFurthermore, in vivo intrathecal inhibition of SPP1 significantly reduced peripheral immune cell migration into the CNS and alleviated disease severity in the EAE model.
primary endpointFurthermore, in vivo intrathecal inhibition of SPP1 significantly reduced peripheral immune cell migration into the CNS and alleviated disease severity in the EAE model.
findingsRESULTS: We identified a distinct MS-inflamed microglia (MIMS) population characterized by high expression of secreted phosphoprotein 1 (SPP1, osteopontin), which is markedly increased in chronic lesions. Integrated transcriptomic and in vitro experiments revealed that microglial SPP1 acts on endothelial cells via an interaction with the Integrin αVβ1 (ITGAV/ITGB1) receptor complex. Mechanistically, this engagement activates the Focal Adhesion Kinase (FAK)/NF-κB signaling cascade, driving the robust expression and dynamic turnover of endothelial adhesion molecules. Crucially, this SPP1-driven endothelial activation enables the massive, pan-lineage recruitment of circulating immune cells without evidence of overt barrier disruption. Furthermore, in vivo intrathecal inhibition of SPP1 significantly reduced peripheral immune cell migration into the CNS and alleviated disease severity in the EAE model.
limitationsTitle: Blocking the microglia-endothelial axis via SPP1-ITGAV disruption attenuates neuroinflammation in multiple sclerosis.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Animals; Osteopontin; Multiple Sclerosis; Microglia; Encephalomyelitis, Autoimmune, Experimental; Endothelial Cells; Female; Mice, Inbred C57BL; Signal Transduction; Humans; Neuroinflammatory Diseases; Integrin alpha4; Inflammation; Mice; Blood-Brain Barrier
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.